TransMedics Group, Inc. Reports Third Quarter 2026 Financial Results

TransMedics Group reported third-quarter 2026 revenue of $203.0 million, up 41% year over year, driven by higher Liver and Heart volumes through its National OCS Program and contributions from logistics services and its PAD Aviation acquisition. Operating income rose to $28.1 million from $23.3 million a year earlier. The company also received full FDA IDE approvals in October for Part B of the OCS ENHANCE Heart trial and the DENOVO Lung trial, and management cited strong momentum entering 2027.